HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / HEOR Feature / Dread Expressed by Public Health Experts on Hurried FDA Signoff on COVID-19 Vaccine

Dread Expressed by Public Health Experts on Hurried FDA Signoff on COVID-19 Vaccine

Eighty-nine sites are enrolling patients in the landmark Phase 3 trial for Moderna Therapeutics vaccine kicked off on Monday, July 27, with the target goal of 30,000 people total, and 15,000 by the end of this week.  Dr. Anthony Fauci, infectious disease expert and advisor to the White House, stated it is “conceivable” (albeit doubtful) to have an answer on the vaccine efficacy in October.

Other experts worry about the accelerated pace and the possibility of truncating the phase 3 trial, although Vice-President Pence stated that there will be no shortcuts or cutting corners.

“The fear is that you wind up doing to a vaccine what [Trump has] already done with [opening] school,” said Dr. Joshua Sharfstein, a former FDA deputy commissioner and a professor at Johns Hopkins University in Baltimore. “Take an important, difficult question and politicize it. That’s what you want to avoid.”

Congressional representatives are preparing a bill requiring FDA to have an expert panel review COVID vaccine trial data and issue a recommendation before FDA Commissioner Stephen Hahn makes a decision on approval.  Committee review is common with past vaccines, relying on examination of all evidence prior to voting on approval and issuing a recommendation to FDA.

Hahn is in the hot-seat with some members of Congress after undercutting confidence in FDA independence when he issued the declaration for hydroxychloroquine for Emergency Authorization Use as a cure for COVID-19.

Data on 30,000 patients may not be necessary for early efficacy detection.  Fauci stated that it is possible that 150-160 cases of disease may give insight.  If about 2/3 of these cases occur in non-vaccinated people, statisticians could deduce that the vaccine had above-60% efficacy.  If efficacy is higher (e.g., 80-90% effective) with an annual rate of infection of >4%, an efficacy signal could be deduced in such a trial with just 50 cases and as soon as three months, reported Ira Longini, a University of Florida biostatistician who designs vaccine trials.

More here.  https://khn.org/news/public-health-experts-fear-a-hasty-fda-signoff-on-vaccine



You might also be interested in:

  • Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
  • [Webinar] How can VA/HTA Inform Policy Interventions and… 10/15/2020
  • Fauci: Trump 'Does Listen' 04/10/2020
  • Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020
  • Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020
  • Can the Fauci Effect Lead to a Larger Pool of Health Care Workers? 01/26/2021
  • Scientist.com to Acquire HealthEconomics.Com, the World’s… 12/15/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute